LEAPMOTOR
28.6.2022 14:02:14 CEST | Business Wire | Press release
Today, Leapmotor's 100,000th mass-produced vehicle rolled off the line. On June 28, 2019, Leapmotor's first mass-produced vehicle, S01, rolled off the line. It took three years from S01 to C11 (the 100,000th mass-produced vehicle), realizing the leap from 0 to 100,000 in the field of intelligent EV. And it only took half a year to reach 100,000 vehicles from 50,000.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005686/en/
Zhu Jiangming, the Founder and Chairman of Leapmotor, said in a thank-you letter that seven years witnessed Leapmotor's winning the trust of 100,000 users. In addition to gratitude, Leapmotor will go forward with more friends by adhering "guard against arrogance, and consistency in original aspiration". We will continue to make breakthroughs and innovation in the core technology field, and focus on the user-centered concept to keep moving with our users, thus delivering the finest smart mobility experience to all consumers.
After seven years of independent full-suite of R&D, the Leapmotor has ushered in a phenomenal development in 2022:
In March, the monthly delivery volume of Leapmotor vehicles exceeded the threshold of 10,000 units for the first time;
In April, launched the first mass-produced model with CTC technology in China - Released the integrated technology of battery chassis of Leapmotor intelligent power CTC;
In May, Leapmotor C01, the electric vehicle equipped with CTC technology without battery pack, launched a pre-sale, and the current order has reached 60000 units; at the same time, the delivery volume reached a new high in May, achieving a year-on-year growth of more than 200% for 14 consecutive months;
In June, the 100,000th mass-produced vehicle was off the production line.
Leapmotor independently controls the core technology. Since 2015, Leapmotor has established a short-term difficult but long-term correct route of full-suite of R&D, striving to build the core competitiveness of technological innovation, which has greatly enhanced Leapmotor's ability to resist external risks under uncertain factors.
Moreover, in order to cope with the uncertainty of the supply chain, Leapmotor also made a layout in advance, built the mechanism of multi supply enterprises and multi-regional planning, and effectively improved the ability of the supply chain to resist risks.
With the further innovation and improvement of Leapmotor product matrix, Leapmotor will brave winds and waves and continue to deliver the finest smart mobility experience to all consumers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 14:06:00 CEST | Press release
Integrated execution model combines multiple disciplines to improve recovery from mature offshore assets Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase reco
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 12:00:00 CEST | Press release
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
